Cytogen sells Targon interest to Elan

Article

After only two years of ownership, biotechnology company Cytogen announced last month that it sold its interest in its subsidiary Targon back to the original owner, pharmaceutical firm Elan of Dublin, Ireland. Elan purchased Targon for $2 million,

After only two years of ownership, biotechnology company Cytogen announced last month that it sold its interest in its subsidiary Targon back to the original owner, pharmaceutical firm Elan of Dublin, Ireland. Elan purchased Targon for $2 million, according to Cytogen. The subsidiary was formed in September 1996 to accelerate the two companies' development of cancer agents (SCAN 10/9/96), and to move Cytogen's work-in-progress agents Prostatec, Oncotec, and prostate-specific membrane antigen (PSMA) toward commercialization.

The Princeton, NJ, company also announced second-quarter results (end-June), posting revenue of $2.5 million, up slightly from $2.2 million for the same period in 1997. The company attributed its increased revenue to sales of ProstaScint, a prostate cancer imaging agent, and Quadramet, a bone pain palliative. ProstaScint earned $1.5 million in the second quarter, and Quadramet earned $253,000, the company reported. Net losses for the quarter were $4.7 million, as compared with $6.4 million in the previous year.

In other Cytogen news, the company named Joseph Reiser to the post of president and CEO, replacing interim chief executive John Bagalay.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.